dc.creatorMOURA, Carlos Geraldo Guerreiro de
dc.creatorMANGUEIRA, Cristovao Luis Pitangueira
dc.creatorCRUZ, Luzia Arlinda Sampaio
dc.creatorCRUZ, Constanca Margarida Sampaio
dc.date.accessioned2012-10-19T18:23:02Z
dc.date.accessioned2018-07-04T15:10:42Z
dc.date.available2012-10-19T18:23:02Z
dc.date.available2018-07-04T15:10:42Z
dc.date.created2012-10-19T18:23:02Z
dc.date.issued2011
dc.identifierNEPHRON CLINICAL PRACTICE, v.118, n.4, p.C355-C360, 2011
dc.identifier1660-2110
dc.identifierhttp://producao.usp.br/handle/BDPI/22890
dc.identifier10.1159/000323388
dc.identifierhttp://dx.doi.org/10.1159/000323388
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1619621
dc.description.abstractIn a cross-sectional study involving 62 patients with systemic lupus erythematosus (SLE), we found that patients with biopsy-proven lupus nephritis (LN) had higher titers of anti-C1q antibodies than active SLE without nephritis patients. Anti-C1q was associated with a negative predictive value of 94.59%, a positive predictive value of 52%, a sensitivity of 86.66% and a specificity of 74.47% for the diagnosis of LN. We conclude that high titers of anti-C1q antibodies are strongly associated with the presence of active LN, and the negative predictive value of this test for diagnosing LN is very high; therefore, it can influence therapeutic decisions and reduce the number of renal biopsies in patients with SLE. Copyright (C) 2011 S. Karger AG, Basel
dc.languageeng
dc.publisherKARGER
dc.relationNephron Clinical Practice
dc.rightsCopyright KARGER
dc.rightsrestrictedAccess
dc.subjectSystemic Lupus Erythematosus Disease Activity Index
dc.subjectAnti-C1q
dc.subjectSystemic lupus erythematosus
dc.subjectLupus nephritis
dc.titleNegative Anti-C1q Antibody Titers May Influence Therapeutic Decisions and Reduce the Number of Renal Biopsies in Systemic Lupus Erythematosus
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución